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Abstract
Background: There are sparse and conflicting data regarding the long-term clinical
course of atopic dermatitis (AD). Although often described as a childhood disease,
newer population-based estimates suggest the prevalence of pediatric and adult dis-
ease may be similar.
Methods: Our objective was to determine whether there is a decline in the preva-
lence of AD in population-based cohorts of patients followed longitudinally beyond
childhood. We conducted a systematic review and meta-analysis including studies
assessing AD prevalence across 3 or more points in time. The primary outcome was
weighted overall risk difference (percentage decrease in AD prevalence).
Results: Of 2080 references reviewed, 7 studies with 13 515 participants were
included. Participants were assessed at 3-6 time points, ranging from age 3 months
to 26 years. The percentage decrease in prevalence after age 12 was 1%, which
was not significantly different from zero (95% confidence interval 2%-5%). Similar
results were found with other age cut-offs.
Conclusion: The prevalence of AD in longitudinal birth cohort studies is similar in
childhood and adolescence/early adulthood.
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1 | INTRODUCTION
Atopic dermatitis (AD), also known as atopic eczema or simply
eczema,1 is one of the most common and burdensome diseases of
childhood, yet little is known about the long-term clinical course of
the disease.2 Textbooks and review articles suggest that most indi-
viduals develop disease within the first 2 years of life, experience
episodic symptoms throughout childhood, and improve by adoles-
cence; yet, sparse and conflicting data exist regarding the proportion
of individuals whose disease resolves and little is known about
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predictors of disease persistence or adult-onset disease.3-5 Challeng-
ing the traditional notion of AD as a predominantly childhood dis-
ease, a growing body of research on the pathophysiology of AD
points to genetic causes of altered skin barrier and immune dysfunc-
tion that could predispose to episodic disease throughout life.6,7
Additionally, population-based estimates from cross-sectional sur-
veys suggest that AD may be as common in adults as in children.8 If
AD prevalence does not decline over time, there are important impli-
cations for patient counseling, management, and future research.
The clinical course of AD has been particularly challenging to
study because the condition is heterogeneous and intermittent. Indi-
viduals have different clinical presentations, and many will have peri-
ods without symptoms or skin lesions. Clinical trials generally focus on
short-term disease control, and cross-sectional studies offer a snap-
shot of the population and hence cannot be used to generate prog-
nostic information for individuals. Thanks to growing interest in atopic
diseases, a number of longitudinal cohort studies included measures
of AD disease activity at multiple time points in the same individuals,
enabling the estimation of changes in AD prevalence as a given popu-
lation ages. The primary objective of this study was to systematically
review and analyze longitudinal studies of AD that include repeated
measurements in the same cohort during and after childhood to test
the hypothesis that the prevalence of AD does not decrease with age.
2 | METHODS
2.1 | Data source and searches
This review is reported in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) and
Meta-analysis of Observational studies in Epidemiology (MOOSE)
guidance.9,10 Our research protocol was registered on PROSPERO
and was publically available prior to the study start date (registration
ID: 42016033553). PubMed and EMBASE were searched from data-
base inception to October 2015 using prespecified search terms,
MeSH (medical subject heading) headings and keywords, developed
in consultation with a professional medical librarian. Search terms
are described in Table S1. Reference lists of included studies were
also screened for additional potentially relevant articles.
This study was exempt from IRB review because it included only
published data and is not considered Human Subjects Research by
the UCSF IRB (http://irb.ucsf.edu/not-human-subjects-research).
2.2 | Study selection
We included studies of patients with AD as diagnosed by a physician
or using a standardized definition such as the UK working party
diagnostic criteria for AD or the International Study of Asthma and
Allergies in Children ISAAC criteria.11,12 Because our objective was
to examine changes in AD prevalence within a given cohort as popu-
lations aged, we included only longitudinal cohort studies that
assessed AD activity in the same patients at 3 or more distinct time
points, to account for the episodic nature of AD and allow for
observation of any nonlinear patterns of change. Further, to capture
AD prevalence beyond childhood, studies were required to include
at least 1 assessment with participants over the age of 12 years. We
chose this cutoff because prior studies suggested high rates of “re-
mission” in adolescence and a longitudinal prospective study sug-
gested that prevalence declines most rapidly between ages 8 and
11.13,14 We excluded studies that were clinic-based, or focused on
patients with localized forms of AD (eg, hand eczema). We did not
select studies on the basis of interventions and our search included
studies in all available languages.
2.3 | Data extraction and quality assessment
Title and abstract screening followed by full-text screening was per-
formed independently and in duplicate to ascertain whether studies
met eligibility criteria. Extracted variables included study information
(authors, year of publication); cohort information (country of study,
cohort name, method of participant recruitment); study size (number
of patients at study start/end, and alternate measures of loss to fol-
low-up); patient characteristics (sex, race/ethnicity, other demo-
graphic information); AD diagnostic criteria; and finally, method and
age of AD prevalence assessment.
Methodological quality was assessed using the Newcastle-
Ottawa Scale for cohort studies.15 The risk of bias and scoring crite-
ria used in the present review are described in Table S2. Screening,
data extraction, and risk of bias assessment were all performed in
duplicate by 2 authors (AY and JO), and discrepancies were resolved
by group consensus (AY, JO, KA, and SML).
2.4 | Data synthesis and analysis
The primary outcome was percentage change in AD prevalence by
age, and all measured time points were included. Secondary out-
comes included the prevalence of other atopic conditions (asthma,
rhinitis/hayfever), treatment information, and severity data. Corre-
sponding authors of included studies were contacted via e-mail to
verify extracted study prevalence data used for the analyses.
We tabulated and plotted the AD prevalence by age for each
study. We then calculated the standardized difference in mean
prevalence before and after the age of 12 years (using all time
points from each study), and report individual study differences and
the mean weighted risk difference. We tested for heterogeneity with
the chi-square test and measured inconsistency using the I2 statistic,
which represents the percentage of total variation across studies.16
Because of the methodologic and clinical heterogeneity inherent in
the data, we used random-effects models for all meta-analyses.
Preplanned sensitivity analyses were conducted to assess the
impact of varying the age cutoffs. The primary analysis was repeated
using different age cutoffs: <10 years vs ≥10 years; <8 years vs
≥8 years. These analyses were performed to test whether our choice
of an age 12 cutoff affected the results. We also repeated the analy-
sis comparing those aged <2 years to 3-11 years and those aged 2-
12 years vs >12 years to test whether including very young children
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(when the diagnosis of AD can be more challenging) affected our
results. Additional stratified analyses were performed to explore
sources of heterogeneity, including analyses by age, by country, by
loss to follow-up, by the number of measurements, and a “jackknife”
analysis that eliminated 1 study at a time. Egger’s test was used to
evaluate for publication bias.17 All analyses were performed with
Stata (version 14, Stata Corporation, College Station, TX, USA).
3 | RESULTS
The search yielded 2080 records. After full-text review of 28
manuscripts, 7 studies were selected for inclusion.14,18-23 The study
flow diagram (Figure 1) lists the reasons why 21 studies were
excluded.
3.1 | Study characteristics
Table 1 outlines the characteristics of each study in detail. The
included studies followed 13 515 individuals. All geographical loca-
tions could be broadly classified as Northern European: Studies were
conducted in Sweden, Iceland, Germany, Denmark, and the UK (3
studies). All studies began follow-up at birth, and most were initiated
the 1980s, with the exception of Williams et al’s study which began
follow-up in 1958, and Ballardini et al, which began follow-up in
1994-1996. Each study measured prevalence at 3-6 separate time
points, which ranged between patient ages of 3 months and
26 years. The annual period prevalence of AD was assessed via
questionnaire in all studies, with the addition of physical examination
at some time points in 3 studies. The diagnostic criteria varied
slightly by study and are outlined in detail in Table S3. Data were
largely unavailable for the secondary outcomes: Only 4 studies
reported data on the prevalence of other atopic outcomes, and the
methods for assessment and reporting differed. None of the studies
reported data on treatment or severity of AD (Table 1).
3.2 | Prevalence estimates
The annual period prevalence of AD ranged from 6% at the age of
26 years22 to 34% at the age of 12 years.21 Study-specific figures
are presented graphically in Figure 2, and the exact numbers used in
the meta-analysis are included in Table S4.
Data on gender were inconsistent. Gough et al observed that
AD prevalence tended to increase with age in the female population,
and decrease among males. Similarly, in Burr et al and Ziyab et al,
AD prevalence in females rose from age of 15 to 23 years and 10 to
18 years, respectively, while declining in males over the same time
period. In contrast, Finnobogadottir et al, and Ballardini et al, did not
find any difference between AD prevalence between males or
females across all time points.
3.3 | Risk difference
The primary outcome was the percentage change in prevalence after
the age of 12 years. This ranged from 0.05 (meaning there was a
5% increase in the prevalence after the age of 12 years, 95% CI:
F IGURE 1 PRISMA flow diagram.
Results of search strategy
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0.03, 0.04)14 to 0.10 (a 10% decrease in prevalence after the age
of 12 years, 95% CI: 0.06, 0.15) (Figure 3).20 The overall mean
weighted percentage difference in prevalence was not significantly
different from 0 (0.01, a 1% decrease, 95% CI: 0.02, 0.050). We
found similar results when we explored multiple age cutoffs in sensi-
tivity analyses (Table S5), and Eggers test showed no significant pub-
lication bias (P = .314). Because of the small number of included
studies, funnel plots were not created.
3.4 | Heterogeneity
There was significant heterogeneity in the primary analysis (I2 96.3%).
Multiple sensitivity analyses were performed to explore the impact of
study design features on the degree of heterogeneity and the out-
come. First, we considered differences in the age structure of the
cohorts: Ballardini et al’s study only followed individuals through the
age of 12 years, while all the other studies followed individuals
F IGURE 2 Longitudinal prevalence estimates of included studies. Proportion of the population with AD at each age
ABUABARA ET AL. | 5
through ages of 18-26 years. Excluding this single study only reduced
the I2 to 93.4%. Secondly, we considered the possibility of chronolog-
ical trends: Williams et al’s study included individuals who were born
in 1958 (2-3 decades prior to the other cohorts); excluding this study
reduced the I2 to 81.9%. Next, we examined whether the disease
definition impacted the heterogeneity: Finnobogadottir et al was the
only study to require eczematous symptoms to have begun in early
childhood, which would have excluded individuals with older-onset
disease from their AD classification and could have made the risk dif-
ference seem especially large. Excluding this study from the meta-
analysis did not change the I2; it remained at 96.3%. In all of these
aforementioned analyses, our overall conclusion that there was no
significant change in the prevalence of AD after the age of 12 years
remained robust. Finally, we tested whether the origin of the study
(UK vs non-UK), and the number of times AD was measured (3-4, 4-
5, or 5-6) affected our estimates. In both cases, there were only mild
reductions in heterogeneity (see Table S5 and Figures S1 and S2).
3.5 | Risk of bias
The included studies had variable risk of bias with Newcastle-Ottawa
scores ranging from 3 to 7 of a total maximum score of 8. One of
the criteria, demonstration that the outcome of interest (ie, AD diag-
nosis) was not present at the start of the study, was not relevant
given that all of the included studies were birth cohorts. In terms of
selection, most (7/9) cohorts were representative of the general
population. The Gough et al and Burr et al studies included only
healthy newborn children with family histories of atopic disease and
therefore may overestimate AD prevalence. Moreover, the Burr
cohort was followed after a randomized controlled trial of milk pro-
tein over the first 4 months of life, which may introduce a bias as
families willing to participate in a RCT may be different from those
who decline. The ascertainment of AD was sometimes self-reported,
but always based on a standardized questionnaire or examination
applied to all participants (Table S6). In Burr et al’s study, the defini-
tion of AD used varied over time and could have introduced bias:
They measured the point prevalence of AD through age of 7 years,
then annual period prevalence from ages 15 and 23 years, which
could make AD rates appear higher during adulthood. A sensitivity
analysis excluding this study did not change the results (Table S5).
All studies had good comparability due to equivalent measurements
between AD and non-AD controls, and all studies had an adequate
length of follow-up. Loss to follow-up was >30% for 3 of 7 studies;
excluding these studies did not affect our results (Table S5 and
Figure S3).
3.6 | Analyses of repeated measures among
individuals
Four studies examined whether individuals reporting AD symptoms at
each age had a history of prior disease. All found that there was sub-
stantial turnover with many new and remitting cases throughout the
study period. However, studies were inconsistent in providing study
definitions of disease “remission” and “persistence” (Table S3). In 1
study, persistence was defined as AD symptoms at 2 or more observa-
tion points at any time within the study18; another required subjects to
have AD symptoms over the course of all study assessments, and across
consecutive observation points.23 This inconsistency in the definition
F IGURE 3 Results of meta-analysis of risk difference in AD prevalence. Risk difference (RD) in prevalence in children age <12 years of age
compared with children age ≥12 years
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of AD persistence and reporting makes it difficult to compare results
across studies.
Multiple studies reported the proportion of patients with new-
onset disease at each age of measurement. Incidence rates were
highest in early childhood, but remained above zero throughout the
teens and early 20s. Williams et al found that of the 870 cases with
examined or reported AD onset by the age of 16 years, 66% had
onset by the age of 7 years. Nissen et al, found the highest propor-
tions of new-onset AD onset before the age of 1.5, and Ballardini
et al reported that over all time periods, the total proportion of new
(vs repeated cases) was 53%.
Multiple studies found that individuals with early-onset AD were
more likely to have symptoms at older ages. In Williams et al, patients
with early-onset AD by the age of 1 year were more likely to have AD
at the age of 23 years (P < .001). Similar findings were presented by
Burr et al, whereby AD onset by the age of 1 year was associated with
AD at the age of 7 and 15 years, and for those with AD at 7 or
15 years, there was an association with AD at the age of 23 years. In
Ziyab et al, of the patients that developed AD by the age of 2 years,
16.9% of patients had AD present at all time points up to the age of
18 years; by contrast, in children who developed AD by the age of
4 years, the proportion with AD at all time points was only 10.9%.
4 | DISCUSSION
In this systematic review and meta-analysis of 7 birth cohort studies
including over 13 000 individuals, we found no significant difference
in AD prevalence before and after childhood. Our finding fills a gap in
the literature about AD in adolescence and early adulthood. It also
highlights the importance of longitudinal analyses to understand the
natural history of an episodic condition. In the studies included in our
review that report on the consistency of individual responses over
time, the presence of AD symptoms was variable. Individuals reported
intermittent periods without symptoms followed by periods with
symptoms again. Because studies did not consistently present
repeated measures of disease activity or severity among individuals,
we are unable to conclude whether AD tends to get better or worse
over time. Nonetheless, the available data suggest that the reason for
steady prevalence estimates across ages is due to a combination of
active disease in both childhood and early adulthood among some
individuals, remission or clearance of disease among others, and later-
onset disease among others.
4.1 | Comparison with other studies
A recent review focused on “AD persistence” concluded that “80%
did not persist by 8 years.”24 It measured the change in the average
proportion of a population reporting AD symptoms upon second
measurement at any age. Upon first glance, these findings may seem
contrary to ours. However, the authors caveat that “it is possible
that some of the patients reported to have AD remittance had unob-
served recurrences later in life.” Thus, although their results are not
directly comparable to ours because they included studies with vari-
able populations, definitions of AD, and timing of follow-up, their
findings also highlight the episodic nature of the condition.
Our results concur with previous work showing high rates of AD
persistence in a longitudinal cohort of children and young adults
treated with pimecrolimus, which may be biased toward more persis-
tent disease.25 This study did not meet inclusion criteria for this
review because enrollment was clinic-based and it included only
patients with AD which did not allow for estimates of disease preva-
lence. The population-based ISAAC studies calculated AD prevalence
at 2 age points in sites around the world, but were cross-sectional in
nature and did not follow the same individuals over time. There was
variation in prevalence by site and by age, but as with our findings,
the average prevalence at both time points was similar (7.9% at the
age of 6-7 and 7.3% at the age of 13-14).26
It is important to highlight that diagnostic definitions may impact
prevalence estimates, possibly biasing toward smaller numbers at older
ages. Notably, the 1 study that required symptom onset occur in “early
childhood” for the definition of AD found the sharpest decline in
prevalence,20 possibly because new-onset cases at later ages were not
included. Other, more commonly used definitions of AD, such as the
classic Hanifin and Rajka criteria and the widely used UK Working
Party Criteria, assign extra points if the AD diagnosis is made in early
childhood.11,27 Subsequently, studies using these criteria may report
smaller numbers of individuals with later-onset disease, which should
be taken into account when considering estimates of adult AD.
4.2 | Strengths and limitations
Major strengths of our review and meta-analysis include the compre-
hensive search, careful selection and critical appraisal of studies, and
inclusion of large representative cohorts followed from birth over 2-
3 decades. Of note, we did not specify the initial age of follow-up in
our review; it was coincidental that all of the studies that met inclu-
sion criteria were designed as birth cohort studies.
Limitations also warrant discussion. First, there is variability in the
terminology used to describe AD: “Atopic dermatitis,” “atopic
eczema,” and “eczema” are all used to refer to the condition.28 In
some settings, “eczema” is considered a less specific term that may
include other types of dermatitis. Therefore, we carefully reviewed
the diagnostic criteria used in each study (Table S3) and assessed the
impact on our results as described above. Second, we found a high
level of statistical heterogeneity between studies. This might be due
in part to the use of a risk difference as our outcome measure, as risk
differences are often less homogeneous.16,29 We used a model with
random effects to help account for the statistical heterogeneity, and
found no appreciable differences in the results after multiple analyses
to address differences in the methods for and timing of AD ascertain-
ment between studies (Table S5). Nonetheless, our results should be
interpreted with caution and replicated as additional follow-up data
from longitudinal cohorts become available. Third, most studies
lacked important information on secondary outcomes including treat-
ment use, disease severity, and other atopic conditions. These data
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may impact the clinical course of AD and are important to report.
Fourth, as is common for studies that follow large cohorts of patients
over decades, attrition was substantial, ranging from 10 to 53%. Most
of the studies (7 of 9) were not designed to specifically study AD,
and none were organized through clinic visits so dropout was likely
random with respect to AD and would therefore be unlikely to bias
prevalence estimates. However, other factors differentially associated
with attrition such as race/ethnicity and socioeconomic status may
also be associated with AD resulting in selection bias.30 These data
should be reported in future longitudinal studies. Finally, all of the
studies identified were from Northern European countries, and
patients were only followed into the third decade of life. Additional
work is needed to understand the clinical course throughout adult-
hood and in more diverse settings.
5 | CONCLUSIONS AND IMPLICATIONS
FOR PRACTICE AND RESEARCH
Our finding of similar AD prevalence before and after childhood sup-
ports the emerging paradigm of AD as a lifelong genetic predisposi-
tion to episodic skin lesions.3 Studies examining predictors of
individual disease course are a high priority for additional research
and can help to elucidate the relationship between genetic suscepti-
bility and environmental influences on the epidemiological trends
described herein.
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